Business NewsPR NewsWire • Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor

Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor

Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor

Spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism Kynos programmes are focused on three key areas: in critical illness post-surgery; in...

View More : https://www.prnewswire.com:443/news-releases/kynos-therapeutics-emerges-from-stealth-with-9-million-financing-and-phase-...
Releted News by prnewswire
Nur ein Jahr nach Markteinführung: ADO (A DECE OASIS) erzielt repräsentatives Jahr mit Rekord über 0,1 Milliarden RMB (16 Mio. USD) an weltweitem Umsatzvolumen
Zacatecas Reports Multiple High Grade Silver Drill Intercepts at Panuco North Including 1.25m at 1440 g/t AgEq in Hole PAN2022-042 and 4.35m at 375 g/t AgEq in Hole PAN2022-44.
Renowned Immunotherapy Expert Dr. Michael Kalos joins Anocca's Scientific Advisory Board
Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor
La carte SIM touristique n°1 en Thaïlande « dtac Happy » accueille les touristes de retour en Thaïlande en doublant gratuitement la validité des cartes SIM
La tarjeta SIM para turistas n.º 1 de Tailandia da la bienvenida a los turistas de nuevo
Thailands Nr. 1 unter den Touristen-SIM-Karten, „dtac Happy", begrüßt Touristen, die nach Thailand zurückkehren, mit einer kostenlosen Verdoppelung der SIM-Karten-Gültigkeit